Novavax reports promising early trial results of COVID-19 vaccine
Washington (AFP) - US biotech company Novavax on Tuesday announced its experimental COVID-19 vaccine elicited a robust immune response, producing more antibodies than are present in recovered patients, and with generally tolerable side-effects in its early-stage trial.The company was given $1.6 billion by the US government last month to develop and fund the drug under Operation Warp Speed -- but in terms of timeline it is behind other firms including Moderna and AstraZeneca which have entered the final stages of their trials.It reported in a press release that the phase one stage of its placeb...
Fujifilm affiliate, Novavax to make COVID-19 vaccine candidate
Fujifilm Corp. said Friday its biotechnology subsidiary and U.S. vaccine maker Novavax Inc. have agreed to manufacture bulk drug substance for the latter's vaccine candidate against the coronavirus disease.The vaccine producer based in Maryland has been developing NVX-CoV2373, a vaccine candidate engineered from the genetic sequence of the new coronavirus, and the Fujifilm subsidiary is expected to bring its leading technical expertise in baculovirus systems and proven manufacturing capacity."We are grateful to partner with the team at Fujifilm Diosynth Biotechnologies to ensure the large-scal...
US awards $1.6 billion to Novavax for COVID-19 vaccine
Washington (AFP) - The US on Tuesday announced it was providing $1.6 billion in funding for the development and manufacture of a COVID-19 vaccine candidate produced by biotech firm Novavax, the largest amount awarded under Operation Warp Speed.Separately, the US also said it was providing $450 million to Regeneron for its experimental COVID-19 treatment and prophylaxis, a combination of two antibodies.Under the terms of its agreement with the Department of Health and Human Services (HHS) and Department of Defense, Novavax agrees to deliver 100 million doses of its vaccine, potentially by the e...
Asian Stocks Lifted By Hopes of Novavax COVID-19 Vaccine
Investing.com -By Gina LeeInvesting.com – Asian stocks were on the rise after U.S. biotechnology company Novavax (NASDAQ:NVAX) raised hopes for a vaccine for the COVID-19 virus.The company has started clinical trials for vaccine and targets preliminary results by July. Phase 2 of the trial will start once phase one is successfully completed, and is expected to take place in several countries including the U.S.“Administering our vaccine in the first participants of this clinical trial is a significant achievement, bringing us one step closer toward addressing the fundamental need for a vaccine ...
COVID-19: Live Updates for Tuesday, May 26
Investing.com -Rolling updates on the latest developments and headlines from around the world on the COVID-19 pandemic.By Gina Lee(9:41 PM ET) Novavax starts clinical trial for novel COVID-19 vaccineU.S. biotechnology company Novavax (NASDAQ:NVAX) started clinical trials for its novel COVID-19 vaccine, targeting preliminary results by July. Phase 2 of the trial, expected to take place in several countries including the U.S., will start once phase one is successfully completed.“Administering our vaccine in the first participants of this clinical trial is a significant achievement, bringing us o...